Multi-Dimensional COVID-19 Chronic Pain Triggers Lower Back, Leg Pain As Virus Appears To Have Long-Lasting Acute Pain Impact On Numerous Organs Of The Human Body; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Non-Invasive Electrotherapy And Bioelectronic Back And Leg Treatments
COVID-19 is baffling to medical institutions, physician specialists and researchers. The global disease is a killer and multi-dimensional attacking lungs, the heart, kidneys and survivors appear to suffer long term after-effects following discharge such as fatigue, lower back pain, breathing irregularities, digestion complications and even neurological ‘brain fog.’ Cured patients complain of long-term effects and consequences. Electromedical Technologies, Inc. (OTCQB: EMED) can offer pain relief for chronic and acute lower back and leg pain through its devices which deliver electrotherapy and bioelectronic treatments.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
Multi-Dimensional COVID-19 Chronic Pain Triggers Lower Back, Leg Pain As Virus Appears To Have Long-Lasting Acute Pain Impact On Numerous Organs Of The Human Body; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Non-Invasive Electrotherapy And Bioelectronic Back And Leg Treatments
COVID-19 Offers A Baffling Combination Of Organ-Attacking Pain, From The Lungs To Kidneys And Back And Leg Chronic Pain
The Global Burden of Disease (GBD) Study published in The Lancet medical journal of London calls the new spike in COVID-19 globally a perfect storm of acute-on-chronic health emergency, launching worldwide attacks on lungs, heart and kidneys causing possible fatal high blood pressure, high cholesterol and, in people between 10-49 years of age, acute lower back pain. The impact of this COVID-19 virus is unprecedented. Electromedical Technologies, Inc. (OTCQB: EMED) can help ease lower back pain through Electrotherapy And Bioelectronic Back and leg treatments without opioid-addicting pain killer drugs.
Some COVID-19 Patients Report Post-Viral Fatigue Lasting 10 Weeks After Discharge
Long term COVID-19 impact includes reports of fatigue up to 10 weeks after hospital discharge, according to a recent article in Pharmacy Times. They report of post-viral fatigue reports in patients thought to have been already cured of COVID-19. Termed as ‘long-haulers’ these patients suffer from chronic and acute pain after surviving the virus initially. Some patients never feel pain from COVID-19 initially but become ‘long haulers’ after hospital discharge, suffering respiratory issues, fatigue, lower back pain and more for months afterward, Pharmacy Times finds in a new survey.
A ‘Perfect Storm’ Of ‘Acute-On-Chronic’ Health Emergency
The Global Burden of Disease (GBD) Study published in The Lancet medical journal of London calls the latest spike in COVID-19 globally a perfect storm of acute-on-chronic health emergency, launching worldwide attacks on lungs, heart and kidneys causing possible fatal after-effects. Patients between 10-49 years of age experience symptoms such as acute lower back pain. Multi-Dimensional COVID-19 Chronic Pain Triggers Lower Back, Leg Pain As Virus Appears To Have Long-Lasting Acute Pain Impact On Numerous Organs Of The Human Body; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Non-Invasive Electrotherapy And Bioelectronic Back And Leg Treatments
Non-Invasive Devices From Electromedical Technologies, Inc. (OTCQB: EMED) Offer Electrotherapy and Bioelectronic treatments To Ease Chronic And Acute Lower Back, Leg Pain
Electromedical Technologies, Inc. (OTCQB: EMED) Offers Chronic And Acute Pain Relief Through its Devices: the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod. Electromedical Technologies, Inc. (OTCQB: EMED) has developed devices such as the FDA-cleared WellnessPro Plus™ and WellnessPro® Pod, to be marketed in the future. These are non-invasive devices which avoid side-effects such as opioid addiction. They deliver to sufferers of chronic and acute pain relief through electrotherapy and bioelectronic non-invasive treatments.
Avoiding Opioid-Addicting Pain Killer Pharmaceuticals
Non-invasive techniques to lower pain levels without the use of addictive opioid pain killers is the subject of intense research. The medical community wishes to avoid opioid-addicting pain killer pharmaceuticals. Prestigious medical institutions and even the National Institutes of Health (NIH) are researching minimally-invasive neuro-stimulation, using electrical impulses to relieve back and leg pain. Multi-Dimensional COVID-19 Chronic Pain Triggers Lower Back, Leg Pain As Virus Appears To Have Long-Lasting Acute Pain Impact On Numerous Organs Of The Human Body; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Non-Invasive Electrotherapy And Bioelectronic Back And Leg Treatments
NIH: Chronic Pain A ‘Primary Driver’ Of Opioid Misuse Disorders
The NIH said, “Chronic pain affects millions of people, lacks effective treatments and and is a primary driver of opioid misuse disorders.” Cleveland Clinic, a prestigious medical institution, is offering multi-disciplinary relief through its Cleveland Clinic-Martin Health pain management center in Florida. Electromedical Technologies, Inc. (OTCQB: EMED) offers Electrotherapy and Bioelectronic treatments through its line of non-invasive devices.
The American Society of Anesthesiologists Seeks Longer-Lasting Treatments
The American Society of Anesthesiologists (ASA) believes that chronic pain management cannot wait for the COVID-19 pandemic to end — it is even more critical during stressful times, it finds. The newest spike, which has triggered renewed lockdowns in Europe and threatens more in U.S. hotspots, has physicians focused on reducing in-person medical visits from patients suffering from chronic and acute pain. Physicians seek treatments that reduce visits needed and offer long-lasting relief of pain for six months or more.
New COVID-19 Spike Means More Acute And Chronic Pain, Possible Future Lockdowns
Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in the field of addressing acute and chronic pain, and sees itself at the forefront of future medicine. Opioid addiction from pain-killer pharmaceuticals is only accelerated by COVID-19. The global pandemic causes patients with chronic pain to limit or avoid physical physician visits, postpone surgical treatments and limit out-of-home mobility — making patients turn to opioid pharmaceuticals pain killer drugs. Multi-Dimensional COVID-19 Chronic Pain Triggers Lower Back, Leg Pain As Virus Appears To Have Long-Lasting Acute Pain Impact On Numerous Organs Of The Human Body; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Non-Invasive Electrotherapy And Bioelectronic Back And Leg Treatments
Electromedical Technologies, Inc. (OTCQB: EMED) Seeks Certification Training For Therapists
StreetInsider.com says electrotherapy and bioelectronic treatments can be helpful in treating chronic and acute pain without addictive drugs. It terms the Electromedical Technologies, Inc. (OTCQB: EMED) devices as in the forefront of the future of medicine. Matthew Wolfson, founder and CEO of EMED, has pursued collaboration with universities and schools on chronic pain research and certification training that offers a ‘Bioelectronics Therapist and Master Device Technician.’ Electromedical Technologies, Inc. (OTCQB: EMED) is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
